SCHEMBL21361517

SCHEMBL21361517

CN(C)c1ccc(S(=O)(=O)N2CCCN(CC3CCCCC3)CCCN(S(=O)(=O)N3CCCCC3)CC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.51
KMT2A Q03164 6/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
LMNA P02545 3/20 0.49
ALDH1A1 P00352 3/20 0.49
GAA P10253 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
HTT P42858 2/20 0.45
USP2 O75604 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
TSHR P16473 2/20 0.43
POLB P06746 1/20 0.43
PKM P14618 1/20 0.43
OPRK1 P41145 1/20 0.42
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24755321 0.99 MEN1 (0.50) MEN1KMT2ASMN1; SMN2LMNAALDH1A1
SCHEMBL21361516 0.94 MEN1 (0.46) MEN1KMT2ASMN1; SMN2LMNAALDH1A1
SCHEMBL24755914 0.91 NPSR1 (0.45) MEN1KMT2ASMN1; SMN2LMNAALDH1A1
SCHEMBL21359145 0.90 ALDH1A1 (0.53) MEN1KMT2ASMN1; SMN2LMNAALDH1A1
SCHEMBL21361494 0.90 CD4 (0.46) MEN1KMT2ASMN1; SMN2LMNAALDH1A1
SCHEMBL24755202 0.90 LMNA (0.42) MEN1KMT2ASMN1; SMN2LMNAALDH1A1
SCHEMBL21361592 0.89 LMNA (0.48) MEN1KMT2ASMN1; SMN2LMNAALDH1A1
SCHEMBL23102233 0.89 TSHR (0.44) MEN1KMT2ASMN1; SMN2LMNAALDH1A1
SCHEMBL23102163 0.89 TSHR (0.44) MEN1KMT2ASMN1; SMN2LMNAALDH1A1
SCHEMBL21361559 0.89 TSHR (0.44) MEN1KMT2ASMN1; SMN2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 US disclosed
WO-2019178510-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2019-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G MEN1 2214/4885KMT2A 4856/4885SMN1; SMN2 4582/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G MEN1 2274/4885KMT2A 4868/4885SMN1; SMN2 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.